Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for treating sleep and cognitive disorders; and Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for treating cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D
| Current Price | ₹275.75 |
|---|---|
| Market Cap | ₹7,272 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services |
| P/E Ratio | -22.7 |
| Return on Equity | -78.80% |
| 52-Week Range | ₹124.11 – ₹299.99 |
| Beta (1Y) | 0.87 |
| Dividend Yield | 0.00% |
1. Research and Development Services-100%
Suven Life Sciences Ltd. is trading at ₹275.75, with a market capitalisation of ₹7,272 Cr.
Suven Life Sciences Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services).
Suven Life Sciences Ltd. has a P/E of -22.7 and a return on equity of -78.80%.